BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38696737)

  • 1. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
    Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
    Burton JM; Youn S; Al-Ani A; Costello F
    J Neurol; 2024 May; 271(5):2662-2671. PubMed ID: 38366070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
    Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.
    Jarius S; Pellkofer H; Siebert N; Korporal-Kuhnke M; Hümmert MW; Ringelstein M; Rommer PS; Ayzenberg I; Ruprecht K; Klotz L; Asgari N; Zrzavy T; Höftberger R; Tobia R; Buttmann M; Fechner K; Schanda K; Weber M; Asseyer S; Haas J; Lechner C; Kleiter I; Aktas O; Trebst C; Rostasy K; Reindl M; Kümpfel T; Paul F; Wildemann B;
    J Neuroinflammation; 2020 Sep; 17(1):261. PubMed ID: 32883348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
    Jarius S; Lechner C; Wendel EM; Baumann M; Breu M; Schimmel M; Karenfort M; Marina AD; Merkenschlager A; Thiels C; Blaschek A; Salandin M; Leiz S; Leypoldt F; Pschibul A; Hackenberg A; Hahn A; Syrbe S; Strautmanis J; Häusler M; Krieg P; Eisenkölbl A; Stoffels J; Eckenweiler M; Ayzenberg I; Haas J; Höftberger R; Kleiter I; Korporal-Kuhnke M; Ringelstein M; Ruprecht K; Siebert N; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; Rostásy K;
    J Neuroinflammation; 2020 Sep; 17(1):262. PubMed ID: 32883358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders.
    Rinaldi S; Davies A; Fehmi J; Beadnall HN; Wang J; Hardy TA; Barnett MH; Broadley SA; Waters P; Reddel SW; Irani SR; Brilot F; Dale RC; Ramanathan S;
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics.
    Lui A; Chong J; Flanagan E; Abrams AW; Krysko KM; Arikan B; Francisco C; Rutatangwa A; Waubant E; Ziaei A
    Mult Scler Relat Disord; 2021 Nov; 56():103253. PubMed ID: 34517190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.
    Ambrosius W; Michalak S; Kozubski W; Kalinowska A
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MOG antibody associated disease (MOGAD) presenting with extensive brain stem encephalitis: A case report.
    Olbert E; Brunner C; Alhani N; Našel C; Struhal W
    eNeurologicalSci; 2022 Dec; 29():100432. PubMed ID: 36388768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and Human Immunodeficiency virus infection: dilemmas in diagnosis and management: a case series.
    Gadama Y; Du Preez M; Carr J; Theron S; Albertyn C; Ssebambulidde K; Saylor D; Brey N; Henning F
    J Med Case Rep; 2023 Oct; 17(1):457. PubMed ID: 37845760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease.
    Wang J; Yang K; Zhang F; Yi Y; Wang J
    Mult Scler Relat Disord; 2023 Sep; 77():104879. PubMed ID: 37442076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
    Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
    Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
    J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.
    Loos J; Pfeuffer S; Pape K; Ruck T; Luessi F; Spreer A; Zipp F; Meuth SG; Bittner S
    J Neurol; 2020 Jun; 267(6):1632-1642. PubMed ID: 32055995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity?
    Zheng Y; Cai MT; Li EC; Fang W; Shen CH; Zhang YX
    Front Immunol; 2021; 12():671425. PubMed ID: 34220818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.